C.R. Bard, Inc. (BCR) Stake Maintained by Marble Harbor Investment Counsel LLC
Marble Harbor Investment Counsel LLC held its position in C.R. Bard, Inc. (NYSE:BCR) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,647 shares of the medical instruments supplier’s stock at the end of the second quarter. Marble Harbor Investment Counsel LLC’s holdings in C.R. Bard were worth $521,000 as of its most recent filing with the SEC.
Several other institutional investors also recently added to or reduced their stakes in BCR. BlackRock Inc. raised its position in C.R. Bard by 1,365.7% in the first quarter. BlackRock Inc. now owns 7,398,081 shares of the medical instruments supplier’s stock worth $1,838,719,000 after buying an additional 6,893,346 shares during the last quarter. MARSHALL WACE ASIA Ltd acquired a new position in shares of C.R. Bard during the first quarter valued at $132,062,000. Marshall Wace North America L.P. acquired a new position in shares of C.R. Bard during the first quarter valued at $132,062,000. Renaissance Technologies LLC raised its position in shares of C.R. Bard by 87.8% in the first quarter. Renaissance Technologies LLC now owns 956,700 shares of the medical instruments supplier’s stock valued at $237,778,000 after buying an additional 447,300 shares in the last quarter. Finally, Alliancebernstein L.P. raised its position in shares of C.R. Bard by 267.0% in the first quarter. Alliancebernstein L.P. now owns 491,184 shares of the medical instruments supplier’s stock valued at $122,079,000 after buying an additional 357,355 shares in the last quarter. Institutional investors and hedge funds own 79.32% of the company’s stock.
C.R. Bard, Inc. (BCR) traded up 0.12% during midday trading on Thursday, reaching $319.44. The company had a trading volume of 31,344 shares. The stock has a market capitalization of $23.21 billion, a PE ratio of 41.94 and a beta of 0.59. C.R. Bard, Inc. has a 1-year low of $203.63 and a 1-year high of $323.27. The firm’s 50 day moving average is $319.82 and its 200 day moving average is $289.48.
C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The firm had revenue of $979.70 million for the quarter, compared to the consensus estimate of $976.53 million. During the same period in the prior year, the business posted $2.54 earnings per share. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, equities analysts anticipate that C.R. Bard, Inc. will post $11.82 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Friday, August 4th. Stockholders of record on Monday, July 24th were issued a $0.26 dividend. The ex-dividend date was Thursday, July 20th. This represents a $1.04 annualized dividend and a dividend yield of 0.33%. C.R. Bard’s payout ratio is 13.67%.
WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.watchlistnews.com/c-r-bard-inc-bcr-stake-maintained-by-marble-harbor-investment-counsel-llc/1534185.html.
Several equities analysts recently weighed in on the company. Zacks Investment Research upgraded C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price target for the company in a research note on Tuesday, June 13th. BidaskClub lowered C.R. Bard from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Jefferies Group LLC restated a “hold” rating on shares of C.R. Bard in a research note on Thursday, August 3rd. Finally, BMO Capital Markets restated a “hold” rating and issued a $317.00 price target on shares of C.R. Bard in a research note on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. C.R. Bard presently has an average rating of “Hold” and a consensus price target of $285.67.
In other news, insider John P. Groetelaars sold 23,687 shares of the stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total value of $7,549,757.51. Following the sale, the insider now directly owns 31,445 shares in the company, valued at $10,022,464.85. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.80% of the company’s stock.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.